ABSTRACT Background Dichotomous responder outcomes, including ≥ 30% and ≥ 50% pain reduction, patient‐reported pain relief, and Patient Global Impression of Change (PGIC), are widely used in trials assessing interventions for neuropathic pain and have been suggested to be comparable, but their differences and influence...
N. Finnerup, S. Gylfadottir, X. Moisset et al.· European Journal of Pain· 0 citations
BACKGROUND
Monoamine reuptake inhibitors are evidenced first-line treatments of peripheral neuropathic pain. The aim was to investigate if bupropion, a drug that specifically inhibits neuronal noradrenaline and dopamine reuptake, relieves neuropathic pain and if a potential effect depends on status of conditioned pain...
M. Kreutzfeldt, M. Carmland, J. V. Holbech et al.· European Journal of Pain· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.